-
Product Insights
Net Present Value Model: Sprifermin
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Sprifermin Drug Details Sprifermin (FGF 18)...
-
Product Insights
Net Present Value Model: Roblitinib
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Roblitinib Drug Details Roblitinib (FGF-401) is...
-
Product Insights
Net Present Value Model: Recifercept
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Recifercept Drug Details Recifercept (TA-46) is...
-
Product Insights
Net Present Value Model: TYRA-300
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model TYRA-300 Drug Details TYRA-300 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TYRA-300
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry TYRA-300 Drug Details TYRA-300 is under development for the treatment of metastatic urothelial carcinoma...
-
Product Insights
Net Present Value Model: RC-28
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model RC-28 Drug Details RC-28 is under...
-
Product Insights
Net Present Value Model: Pegbelfermin
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Pegbelfermin Drug Details Pegbelfermin (BMS-986036, PEG-FGF21,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ethamsylate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ethamsylate Drug Details Ethamsylate is under development for the treatment of dry (atrophic) macular...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ABSK-061
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ABSK-061 Drug Details ABSK-061 is under development for the treatment of solid tumors including urothelial...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – roblitinib
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry roblitinib Drug Details Roblitinib (FGF-401) is under development for the treatment of solid malignancies...